Get my own profile
Public access
View all13 articles
5 articles
available
not available
Based on funding mandates
Co-authors
- Brad H NelsonDirector, Deeley Research Centre, BC Cancer AgencyVerified email at bccancer.bc.ca
- Kelly McNagnyU of British ColumbiaVerified email at brc.ubc.ca
- Spencer D. Martin, MD PhDFaculty of Medicine, University of British columbiaVerified email at vch.ca
- Robert A. HoltHead of Sequencing, Michael Smith Genome Sciences Centre, BC Cancer Agency Distinguished ScientistVerified email at bcgsc.ca
- David KroegerAssociate Director BD, Zymeworks Inc.Verified email at usask.ca
- Eric TranEarle A. Chiles Research Institute, Providence Cancer CenterVerified email at providence.org
- Kwame Twumasi-BoatengTelix PharmaceuticalsVerified email at telixpharma.com
- Ryan MorinProfessor, Simon Fraser University; Scientist at Genome Sciences Centre, BC Cancer AgencyVerified email at sfu.ca
- Randy D GascoyneProfessor of Pathology, University of British ColumbiaVerified email at bccancer.bc.ca
- Mauro CastellarinResearch Associate, University of Pennsylvania, Center for Cellular ImmunotherapiesVerified email at pennmedicine.upenn.edu
- Zabrina BrummeAssociate Professor, Faculty of Health Sciences, Simon Fraser UniversityVerified email at sfu.ca
- Michael R. HughesThe University of British ColumbiaVerified email at brc.ubc.ca
- Julia SalzmanAssociate Professor, Stanford UniversityVerified email at stanford.edu
- Marco MarraBC Cancer Agency; University of British Columbia, Genome Sciences CentreVerified email at bcgsc.ca
Follow
Julie S. Nielsen
Leader, Cell Manufacturing, BC Cancer's Immunotherapy Program
Verified email at bccancer.bc.ca